| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 169.09 | 824 |
| Intrinsic value (DCF) | 2.56 | -86 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 3742.20 | 20349 |
Apollomics, Inc. (NASDAQ: APLM) is a clinical-stage biotechnology company focused on developing innovative oncology therapies to address unmet medical needs in cancer treatment. Headquartered in Foster City, California, with operations in China and Australia, the company specializes in precision medicine targeting hard-to-treat cancers. Its lead candidate, APL-101 (Vebreltinib), is a selective c-Met inhibitor in development for non-small cell lung cancer (NSCLC) and other advanced solid tumors. The pipeline also includes APL-102, a multi-kinase inhibitor for liver, breast, and esophageal cancers, and APL-122, a brain-penetrant tumor inhibitor. Formerly known as CBT Pharmaceuticals, Apollomics leverages a global R&D strategy to advance novel therapies, positioning itself in the competitive immuno-oncology and targeted therapy space. With no approved products yet, the company’s valuation hinges on clinical progress, particularly in NSCLC and rare cancers where c-Met dysregulation plays a key role.
Apollomics presents a high-risk, high-reward opportunity for investors with a tolerance for biotech volatility. The company’s focus on niche oncology targets (e.g., c-Met) offers differentiation, but its pre-revenue status and significant net losses ($53.9M in FY2023) underscore reliance on clinical milestones and funding. Key catalysts include APL-101’s Phase II data in NSCLC and potential partnerships. Risks include trial failures, cash burn ($28.7M operating cash outflow in 2023), and competition from established oncology players. The modest market cap (~$7.8M) and low beta (0.92) suggest limited liquidity but lower systemic risk. Investors should monitor enrollment progress in China-based trials and regulatory feedback.
Apollomics competes in the crowded targeted oncology space, where its differentiation lies in targeting c-Met and multi-kinase pathways with a focus on Asian markets. APL-101’s niche is NSCLC with MET exon 14 skipping mutations, competing with Merck’s Tepmetko (tepotinib) and Novartis’ Tabrecta (capmatinib), but Apollomics’ oral formulation and potential CNS activity could offer advantages in brain metastases. The company’s asset APL-102 faces stiff competition in liver cancer from Bayer’s Nexavar (sorafenib) and Roche’s Tecentriq combinations. Apollomics’ lean structure and China-based trials may reduce costs and accelerate enrollment, but its lack of commercial infrastructure necessitates partnerships. The primary competitive moat is IP around its kinase inhibitors, though clinical efficacy will determine long-term positioning. Compared to larger peers, Apollomics’ early-stage pipeline lacks diversification, increasing binary risk.